AUTHORS
Asha Jose, PhD, Hanga Horvath2, Isabelle Demeritt3, Pavan Bendapudi, MD4, Henriette Farkas, PhD5, Steven Philip Grover, PhD6
AFFILIATIONS
1 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
2 Semmelweis University, Budapest, Hungary
3 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
4 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
5 Semmelweis University, Budapest, Hungary
6 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
ABSTRACT
Introduction: C1 inhibitor (C1INH) is a multifunctional serine protease inhibitor that serves as a major negative regulator of several biological pathways including the contact pathway of coagulation. Congenital C1INH deficiency causes hereditary angioedema (HAE) that is characterized by recurrent episodes of swelling. HAE resulting from C1-inhibitor deficiency (C1INH-HAE) has been associated with a systemic procoagulant state and an increased risk of venous thromboembolism. However, the molecular mechanism by which C1INH deficiency leads to the induction of a systemic procoagulant state remains unknown.
Aim: To investigate the molecular mechanisms by which C1INH deficiency promotes activation of coagulation using mouse models, cell culture systems, and patient plasma samples.
Methods: C1INH-deficient mice were treated with pharmacologic inhibitors targeting plasma kallikrein (PKa), activated factor XII (FXIIa), activated factor XI (FXIa), bradykinin receptors, or tissue factor (TF), and plasma levels of thrombin-antithrombin (TAT) complexes measured. The effect of bradykinin stimulation on cell surface FXa procoagulant activity and macromolecular vascular permeability of 60 kDa FITC-dextran was assessed in cultured human umbilical vein endothelial cells (HUVEC). In complementary studies, markers of activation of coagulation, including prothrombin fragment 1+2 (F1+2), TAT, D-dimer and thrombin generation, were measured in the plasma of a small cohort of patients with C1INH-HAE (n=6) before and at 1, 3 and 6 months after initiation of treatment with the anti-PKa monoclonal antibody lanadelumab.
Results: In vivo, inhibition of PKa, but not FXIIa or FXIa, significantly reduced plasma TAT levels in C1INH-deficient mice, indicating a non-canonical mechanism of coagulation regulation independent of downstream intrinsic pathway activation. Further supporting this non-canonical mechanism, inhibition of bradykinin receptors or tissue factor also significantly reduced plasma levels of TAT in C1INH deficient mice. In vitro, bradykinin stimulation had no effect on endothelial cell surface TF-dependent FXa generation on HUVECs. However, bradykinin stimulation significantly increased macromolecular permeability of HUVEC monolayers, as evidenced by enhanced transendothelial flux of 60 kDa FITC-dextran. These findings are consistent with a mechanism in which, upon bradykinin stimulation, FVII and FX can cross the endothelium and complex with subendothelial tissue factor to form the extrinsic Xase, supporting activation of coagulation. Critically, in patients with C1INH-HAE, treatment with the PKa inhibitor lanadelumab significantly reduced plasma levels of F1+2, TAT complexes, and D-dimer without altering contact pathway-initiated thrombin generation.
Conclusion/Implications: Taken together, these data suggest that the procoagulant state associated with C1INH deficiency is mediated by a novel, non-canonical mechanism whereby excessive PKa-induced bradykinin generation enhances vascular permeability, likely enabling plasma zymogens to access subendothelial tissue factor, promoting activation of coagulation. These data highlight the potential of PKa inhibitors to ameliorate the procoagulant state observed in patients with C1INH-HAE.
DISCLOSURES
Asha Jose, PhD: No relevant conflicts of interest to declare.